Elutia (NASDAQ:ELUT) Director Buys $15,900.00 in Stock

Elutia Inc. (NASDAQ:ELUT) Director Guido Neels acquired 15,000 shares of the company’s stock in a transaction dated Wednesday, January 28th. The shares were purchased at an average cost of $1.06 per share, with a total value of $15,900.00. Following the acquisition, the director owned 83,750 shares of the company’s stock, valued at approximately $88,775. This represents a 21.82% increase in their position. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Elutia Price Performance

Shares of ELUT opened at $1.05 on Friday. The company has a market capitalization of $44.84 million, a P/E ratio of -1.14 and a beta of 0.62. Elutia Inc. has a one year low of $0.50 and a one year high of $3.46. The business’s 50 day simple moving average is $0.71 and its 200-day simple moving average is $1.17.

Elutia (NASDAQ:ELUT) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.15. The business had revenue of $3.32 million during the quarter, compared to the consensus estimate of $6.65 million. On average, sell-side analysts anticipate that Elutia Inc. will post -1.74 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have issued reports on ELUT shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Elutia in a report on Wednesday, January 21st. Wall Street Zen upgraded Elutia to a “sell” rating in a research report on Saturday, November 8th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $7.00.

Institutional Investors Weigh In On Elutia

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ELUT. XTX Topco Ltd bought a new position in Elutia during the second quarter worth about $28,000. Jane Street Group LLC bought a new stake in shares of Elutia in the 1st quarter valued at about $48,000. Virtu Financial LLC acquired a new stake in shares of Elutia in the 3rd quarter valued at approximately $26,000. Arcus Capital Partners LLC boosted its stake in Elutia by 50.3% during the 2nd quarter. Arcus Capital Partners LLC now owns 30,050 shares of the company’s stock worth $59,000 after acquiring an additional 10,050 shares during the last quarter. Finally, FNY Investment Advisers LLC acquired a new position in Elutia during the fourth quarter valued at approximately $25,000. Institutional investors own 74.03% of the company’s stock.

About Elutia

Elutia, Inc is a biopharmaceutical company focused on the development of novel nitric oxide therapies based on its proprietary polymeric nitric oxide platform. This technology is designed to enable sustained, controlled release of nitric oxide to targeted tissues, potentially overcoming the delivery challenges associated with gaseous nitric oxide and small?molecule donors.

The company’s lead program is in preclinical development for pulmonary arterial hypertension, with additional research efforts aimed at other cardiovascular and respiratory conditions.